15年单中心血透通路再干预负担与通畅率
该研究回顾性分析2009-2024年单中心871例上肢动静脉通路(648例自体内瘘,223例移植物),评估各构型通畅率及再干预负担。结果显示1年原发通畅率因构型而异(移植物仅36.2%),移植物再干预负担约为自体内瘘的4.4倍,高secondary通畅率以显著再干预为代价。
要点
- 移植物1年原发通畅率36.2%,显著低于各类自体内瘘。
- 移植物再干预负担为1.09次/通路年,自体内瘘为0.25次/通路年,相差约4.4倍。
- 移植物、女性、缺血性心脏病和糖尿病是原发通畅丧失的独立预测因素。
核心结论
- 高secondary通畅率以大量再干预为代价,且再干预集中于移植物。
- 移植物维持所需再干预约为自体内瘘的4.4倍。
研究设计与样本
- 回顾性分析2009至2024年单中心810例患者的871例连续上肢动静脉通路(648例自体内瘘,223例移植物)。
- 中位随访14.7个月,采用Kaplan-Meier法估计通畅率,多因素Cox回归分析预测因素,并以肾移植为竞争事件进行竞争风险分析。
主要发现
- 总体原发、辅助原发和secondary通畅率在1年分别为60.3%、87.1%和96.8%,2年分别为50.5%、81.5%和95.7%,3年分别为44.6%、77.1%和94.1%。
- 1年原发通畅率因构型而异:桡动脉-头静脉瘘70.1%,肱动脉-头静脉瘘63.3%,贵要静脉转位71.6%,移植物36.2%(P < .001)。
- 2211个通路年共进行743次维持通畅的干预(0.336次/通路年),37.2%的通路至少需要一次再干预。
- 移植物再干预负担为1.09次/通路年,自体内瘘为0.25次/通路年,相差约4.4倍。
- 移植物(HR 2.39,95%CI 1.86-3.06)、女性(HR 1.37,95%CI 1.10-1.71)、缺血性心脏病(HR 1.42,95%CI 1.04-1.94)和糖尿病(HR 1.26,95%CI 1.00-1.57)独立预测原发通畅丧失;竞争风险分析中移植物再干预的亚分布HR为2.32。
临床怎么用
- 在通路规划时优先考虑自体内瘘,并根据构型告知患者再干预负担。
- 对移植物通路患者应预期更高的再干预频率并加强监测。
局限性
- 单中心回顾性设计可能限制普遍性。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Maintaining a hemodialysis access typically requires repeated intervention, yet the cumulative reintervention burden-as distinct from patency-is rarely quantified, and configuration-specific estimates from Asian centers are scarce. We evaluated patency and quantified the configuration-specific reintervention burden of upper-extremity arteriovenous accesses over 15 years at a single center. METHODS: We retrospectively analyzed 871 consecutive upper-extremity arteriovenous accesses (648 fistulas; 223 grafts) created in 810 patients between 2009 and 2024. Every subsequent procedure was adjudicated from operative records as patency-maintaining or access-abandoning; operations unrelated to the access under study, including kidney transplantation, catheter procedures, and peripheral arterial interventions, were excluded. Patency was estimated by the Kaplan-Meier method according to accepted reporting standards and compared across configurations-radiocephalic fistula, brachiocephalic fistula, basilic vein transposition, and graft. The reintervention burden was expressed as interventions per access-year. Predictors of loss of primary patency were assessed by multivariable Cox regression, and a competing-risk analysis treated kidney transplantation as a competing event. RESULTS: Median follow-up was 14.7 months. Overall primary, assisted-primary, and secondary patency were 60.3%, 50.5%, and 44.6%; 87.1%, 81.5%, and 77.1%; and 96.8%, 95.7%, and 94.1% at 1, 2, and 3 years, respectively. One-year primary patency differed by configuration: 70.1% for radiocephalic fistulas, 63.3% for brachiocephalic fistulas, 71.6% for basilic vein transpositions, and 36.2% for grafts (P < .001). Across 2211 access-years, 743 patency-maintaining interventions were performed (0.336 per access-year), and 37.2% of accesses required at least one reintervention. The burden was concentrated in grafts: 1.09 interventions per access-year for grafts versus 0.25 for autogenous fistulas, an approximately 4.4-fold difference. Graft configuration (hazard ratio, 2.39; 95% confidence interval, 1.86-3.06), female sex (1.37; 1.10-1.71), ischemic heart disease (1.42; 1.04-1.94), and diabetes (1.26; 1.00-1.57) independently predicted loss of primary patency. Findings persisted after excluding maturation-assisting procedures and in the competing-risk analysis (graft subdistribution hazard ratio for reintervention, 2.32). CONCLUSIONS: High secondary patency was achieved at the cost of substantial reintervention concentrated in grafts, which required roughly 4.4 times the maintenance of autogenous fistulas. Reporting an explicit reintervention burden alongside patency supports autogenous-first, configuration-aware access planning and patient counseling.
引用
- Cho S, Joh JH. Reintervention Burden and Patency of Hemodialysis Vascular Access in a 15-Year Single-Center Cohort. J Vasc Surg. 2026. PMID: 42880613. doi:10.1016/j.jvs.2026.09.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。